BioSpace News Archive

Veozah, an oral once-daily medication, is the first FDA-approved NK3 receptor antagonist for hot flashes, a common symptom of menopause that can affect health and quality of life.

The company’s second antibody-drug conjugate deal of 2023, with Shanghai-based LaNova Medicines, adds a potential first-in-class GPRC5D-directed ADC for multiple myeloma.

The precision neuroscience startup has notched $109 million in seed, Series A and B financing as it looks to further develop a Phase I candidate to treat a rare X-linked neuromuscular disorder.

ReCode plans to use its SORT LNP genetic medicines delivery technology to treat CF and PCD patients who don’t respond to current treatments.

Beckman Coulter, a clinical diagnostics leader, unveiled the DxI 9000 Access Immunoassay Analyzer, the most productive immunoassay analyzer per footprint.

150 patients have been enrolled at the multi-clinical centers in US to the Phase 3 randomized trial of DFP-10917 vs non-intensive reinduction or intensive reinduction in the 2nd, 3rd, or 4th salvage of AML and the 1st interim analysis of this study shall be done for NDA approval to the FDA in US soon after confirmation of the superiority of DFP-10917 arm.

Biophytis SA announced that it has submitted the application for Clinical Trial Authorization to initiate SARA-31, the first phase 3 study in sarcopenia, on the European portal of the EMA.

RaySearch Laboratories AB is pleased to announce that the strategic partnership with BEBIG Medical, which began in 2018, has been extended through a memorandum of the agreement.

BioNxt Solutions Inc. is pleased to report that it has received government approval for to proceed with its comparative drug absorption study for the Company’s transdermal Rotigotine patch for the treatment of Parkinson’s disease.

Alvotech, a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced the release of its second annual Equality Report covering 2022.